Table 4.
The m6A protein alterations are correlated with clinicopathological features
| Cancer | Regulator | Alteration | Prognosis | Metastasis/Invasion | Tumor size | Tumor stage | Histological grade | Recurrence | Therapy | Refs |
|---|---|---|---|---|---|---|---|---|---|---|
| AML | METTL3/ WTAP | Overexpression | Poor | [41, 43] | ||||||
| AML | METTL3/METTL14/YTHDF1/YTHDF2/FTO/ALKBH5 | Mutation | Poor | [142] | ||||||
| GBM | METTL3 | Overexpression | Poor | Radioresistance | [48] | |||||
| GBM | WTAP/RBM15/YTHDF1/ ALBKH5 | Overexpression | Poor | Increase | [49] | |||||
| LC | METTL3 | Overexpression | Poor | Lymph node metastasis Brain metastasis | Increase | Worsen | [54, 55] | |||
| LC | FTO/ IGF2BP1 | Overexpression | Poor | [56, 59] | ||||||
| HCC | METTL3/YTHDF1 | Overexpression | Poor | Worsen | [58, 121] | |||||
| HCC | KIAA1429/ IGF2BP1 | Overexpression | Poor | [59, 63] | ||||||
| HCC | WTAP | Overexpression | Poor | Prone | [64] | |||||
| HCC | METTL14 | Down-regulation | Better | Weaken | Decrease | [100] | ||||
| HCC | YTHDF2 | Overexpression | Poor | Microvascular invasion | Worsen | [65] | ||||
| CRC | METTL3 | Overexpression | Poor | Lymph node metastasis Liver metastasis Distant metastasis | Prone | Chemotherapy resistance | [67, 68, 70] | |||
| CRC | METTL3 | Down-regulation | Better | Decrease | [103] | |||||
| CRC | METTL14 | Down-regulation | Better | Weaken | Decrease | [104] | ||||
| CRC | FTO | Overexpression | Poor | Increase | Worsen | [71] | ||||
| CRC | YTHDC2 | Overexpression | Poor | Lymph node metastasis | Worsen | [74] | ||||
| CRC | YTHDF1 | Overexpression | Poor | Lymph node metastasis Distant metastasis | Worsen | [75] | ||||
| CRC | IGF2BP2 | Overexpression | Poor | [77] | ||||||
| PDAC | METTL3 | Overexpression | Poor | Worsen | [78] | |||||
| GC | METTL3 | Overexpression | Poor | [80] | ||||||
| BCA | METTL3 | Overexpression | Poor | Worsen | Increase | [82] | ||||
| BCA | METTL14 | Down-regulation | Better | Weaken | [106] | |||||
| PCA | YTHDF2 | Overexpression | Poor | Increase | [85] | |||||
| RCC | METTL3 | Down-regulation | Better | Decrease | Decrease | [107] | ||||
| RCC | FTO | Down-regulation | Better | Weaken | [108] | |||||
| RCC | WTAP | Overexpression | Poor | Increase | Worsen | [87] | ||||
| CSCC | FTO | Overexpression | Poor | Worsen | Increase | [88] | ||||
| BC | METTL3 | Overexpression | Poor | [143] | ||||||
| BC | FTO | Overexpression | Poor | Increase | [94] | |||||
| EOC | METTL3 | Overexpression | Poor | Worsen | Increase | [95] | ||||
| EOC | ALKBH5 | Overexpression | Poor | Worsen | Increase | [96] | ||||
| EOC | IGF2BP1 | Overexpression | Poor | [59] | ||||||
| Melanoma | FTO | Overexpression | Poor | Worsen | [97] | |||||
| Melanoma | YTHDF1 | Down-regulation | Better | Weaken | [110] |
AML acute myeloid leukemia; GBM glioblastoma; LC lung cancer; HCC hepatocellular carcinoma; CRC colorectal cancer; PDAC pancreatic cancer; GC gastric carcinoma; BCA bladder cancer; PCA prostate cancer; RCC renal cell carcinoma; CSCC cervical squamous cell carcinoma; BC breast cancer; EOC epithelial ovarian cancer